ESLA | Estrella Immunopharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0350 - 1.2900
52 Week Range	0.8100 - 20.80
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	5,198
Average Volume	92,312
Shares Outstanding	36,376,300
Market Cap	40,013,930
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-09-14

Valuation
Profitability
Growth
Health
P/E Ratio	-4.23
Forward P/E Ratio	N/A
EPS	-0.26
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	0
Country	USA
Website	ESLA

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

*Chart delayed

Analyzing fundamentals for ESLA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ESLA Fundamentals page.

Watching at ESLA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ESLA Technicals page.